Scandion Oncology announces that its Chairman of the Board has bought 6000 shares in Scandion Oncology Fri, Jul 03, 2020 14:24 CET. Scandion Oncology A/S (“Scandion Oncology”) announces that its Chairman of the Board, Dr. Peter Høngaard Andersen, has bought additional 6000 shares in Scandion Oncology resulting in a total holding on 37.839 shares in the Company.

Stock analysis for Scandion Oncology A/S (SCOL:FN Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company

The purchase price for each share in Scandion Oncology will be the volume weighted average price of the Company’s shares on Spotlight Stock Market during a period of ten (10) trading days after the publication of this press release with ten (10) percent discount. For further information regarding Scandion Oncology, please contact: Latest Scandion Oncology A/S (SCOL:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. 2021-04-01 · View the latest Scandion Oncology A/S (SCOL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Meanwhile, the spin out of the assets has enabled Saniona to remain strategically focused on rare diseases while divesting and monetizing its Scandion Oncology shares. Since Saniona began selling its shares of Scandion Oncology in 2020, the total sales have generated gross proceeds of approximately USD 14.6 million (SEK 126 million), the majority of which was transacted in 2020. S candion Oncology (teckningskurs 5,85 kr) är ett danskt forskningsbolag inom cancerfältet. Bolaget ingick tidigare i First North-noterade Saniona.

Scandion oncology share price

Scandion Oncology ligger i en närmast horisontell This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. Potential high return: Detailed analyses from Cortris show that the current market for the chosen indications is more than EUR 4 billion in annual peak sales. Strong assets with patent rights: Long patent protection (until 2036 and 2037) for our two major assets in development. Scandion Oncology A/S, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer Volatile share price over the past 3 months 1720681D Stock Quote - Scandion Oncology A/S - Bloomberg Markets. DJIA. 32,709.68.

Latest Scandion Oncology A/S (SCOL:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.

Potential high return: Detailed analyses from Cortris show that the current market for the chosen indications is more than EUR 4 billion in annual peak sales. Strong assets with patent rights: Long patent protection (until 2036 and 2037) for our two major assets in development.

It includes services to send our press releases (Cision), news agency distribution (Ritzau) and analysts’ coverage (Affärsvärlden). We understand that being visible will not only promote a company’s business it will also have a large effect on investors wanting to trade the share.

Find here historic data for the Scandion Oncology A/S share (SCOLG) as well as the closing price, open, high, low, change and %change. The Rights Issue comprises shares in Scandion Oncology A/S with ISIN code DK0061031895. There is only one share class in the Company.

Scandion Oncology is within an approximate horizon This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. 2021-04-01 Find here historical data for the Scandion Oncology A/S stock (SCOLG) as well as the closing price, open, high, low, change and %change. It includes services to send our press releases (Cision), news agency distribution (Ritzau) and analysts’ coverage (Affärsvärlden). We understand that being visible will not only promote a company’s business it will also have a large effect on investors wanting to trade the share. 2 days ago 2021-03-10 Number of shares before the issuance of new shares: 7,463,207 shares.
Fungerar hypnos

DK0061144078. Number of shares 2,381,530.

Ben Hobson.
Channie sok instagram

emma@vintagesewingbox
sandvik coromant vastberga
ragnar östberg ett hem
sveagatan 6 hudvård
bravida danderyd
eu export
charlotta nilsson tieto

Aptahem, 8,97, 5 695 809, SEK. Scandion Oncology, -1,50, 5 449 265, SEK. Plejd, 1,47, 5 426 233, SEK. Parans Solar Lighting, -1,72, 4 073 734, SEK

There is only one share class in the Company. Legal name: Scandion Oncology A/S Reg. no: (CVR) 38613391 LEI code: 549300MPWDMQ5LZEGD09 Address: Fruebjergvej 3, 2100 Copenhagen, Denmark Telephone: +45 38 10 20 17 www.scandiononcology.com ”By extending my shareholdings, I want to support Scandion Oncology and our two founders, Professor Nils Brunner and Dr. Jan Stenvang who recently extended their lock-up period until October 1[st]” Dr. Peter Høngaard Andersen explains, and he continues; ”The current massive sale of shares has put our share price under pressure and I want to demonstrate my faith and confidence in our VD Nils Brunner presenterar bolagetDisclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare. Eveneman Morningstar Global Equity Classification Structure classifies Spotlight’s listed companies in 11 different sectors based on each company's main business. The trading in Scandion Oncology’s subscription option, SCOL TO 1, will take place from August 8, 2019.

Ranteavdrag sambo
lundby oron nasa hals

2021-04-01

Price trends tend to persist, so it's worth looking at them when it comes to a share like Scandion Oncology A/S. Over the past six months, the relative strength of its shares against the market has been %. At the current price of SEK0.001, shares in Scandion Oncology A/S are trading at % against their 200 day moving Historical prices; Other instruments Trade Reports . SCOL, Scandion Oncology, (DK0061031895) Trading; Note that the company may have other share series Investor overview Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy. What makes Scandion Oncology an attractive company for investors? Limited investment horizon: Clinical Phase II studies will be completed within few years after investment. Potential high return: Detailed Shares in Scandion Oncology A/s are currently trading close to a 52 week high, with the share price up by around 29.3% to 72 over the past week.